=	Ĩ	
ſ	1	1
	T	Ì
⋖	<	<i>-</i>
ſ	T	٦
	_	

•							Alfar	lment to Page	No 5		Page 1 of 5		
•	INF O 1 P	ORMAT			TO 144 LOSUR	E STATE		ATTY. DOCK 0125-0016D2			Page 1 of 5 APPLICATION 09/939,832	오	
	OCT O	15. E.S.	1	B	ري 10y 0 4	2003		APPLICANT(S McTigue et al.	•	<u>.</u>		CENTER	OCT 0
PATE	1	0 E	\ \{\int_{\int}		& MADE	MERKER		FILING DATE August 28, 200			GROUP 1631	1600/290	3 2001
							U.S. P.	ATENT DOCU	MENTS				
	EXAM INITIA				DOC!	UMENT BER	DATE	NAME		CLASS	SUB-CLASS	FILING DA	ATE
			AA1		4,966	·	10/30/90	Valee et al.		435	199		
			AB1		5,217		6/8/93	Levitzki, et. al		514	613		
			AC1		5,302		4/12/94	Spada et al.		514	357	ļ	
	<u> </u>		AD1		5,330	,992	7/19/94	Eissenstat, et.		514	312	<u> </u>	
	EXAM	INED	T		DOC	UMENT	DATE	PATENT DOC			GI ID CI A CC	TTD A NICK A TO	7077
	INITIA		ļ		NUM	BER				CLASS	SUB-CLASS	TRANSLAT	ION
		R	AEI		WO9.	1/15495	1991	wo			<del> </del>	□Yes □ No	
			AF1		WO92	2/20642	1992	wo				□Yes □ No	
			AG1		WO92	2/21660	1992	WO			-	□Yes □ No	
			AH1		WO94	1/03427	1991	WO				□Yes □ No	٠,٠
	-	j	AI1		WO94	1/10202	1994	wo				□Yes □ No	
	P		AJ1		WO 9	8/49300	11/5/98	WO				□Yes □ No	
١			_L		C	THER (I	ncluding Au	thor, Title, Date	. Pertinent	Pages, et	(c.)		
		us.	AK	1				Ophthalmol., 1					
			AL	1		Agouror Block A	Pharmaceungiogenesis	iticals, Inc. "Ago : Human VEGF	ouron Solv Receptor 2	es Structu 2 Kinase"	re of Key Target, March 4, 1999.	for Drugs to	
ľ			AM	1		Bazenet	et al., Mol.	Cell. Biol., <u>16</u> :6	926-6936	(1996)			
			AN	1		Borgströ	m et al, <u>Car</u>	ncer Res., 56:403	32-4039 (1	996)			
			AO	1			H.R., et al., 3, pages 9-2		l Pharmace	ology, 3 <sup>rd</sup>	Edition (Katzung	g et al., eds	
	AP 1 Choudhury et al., FE							FEBS Letters, 282(2):351-354 (May, 1991)					7
	<b></b>		AQ	1		Dvorak e	et al., <u>Am. J</u>	Path., 146:1029	9-1039 (19	95)	100	<u> </u>	<del>0 7 2003</del>
			AR	1		DeVries	et al., <u>Scien</u>	<u>ce, 255</u> :989-991	(1992)	·		(1994) (1994)	<del>- 73</del>
		V	AS	1		Dougher	-Vermazen	et al., Biochem.	Biophys. F	Res. Com	<u>m., 205</u> :728-738 (	(1994)	
	EXAMI	NER _	They	/	2	<del></del>	····	DATE	CONSIDE	RED	H-07		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



	FORM	PTO 144	49		ATTY. DOCKET	 NO.	APPLICATION	NO.		
					0125-0016D2		09/939,832			
INFORMAT	ION DIS	CLOSUR	ESTATE	MENT			<u>L</u>		<u></u>	
OIP	E	/		6.7	APPLICANT(S)			Ž	<del>C</del> T	
	4		n /	2003	McTigue et al.			帚	0	
0 700	4 3000 4 3000	\ \_<	, KON U 4 DOWN . ST		FILING DATE		GROUP		3 2001	
( OCT O	ي 2000 ا		E.	18 /	August 28, 2001		1631	8	00	
T.			CETTADEMER		ATENT DOGUNGE	ATTC		1600/290	<del></del>	
EXAMINER	OKCHURA	DOC	UMENT	DATE	ATENT DOCUMENT NAME	CLAS	S SUB-CLASS		TE	
INITIAL		NUM			TATALLE .	CLAS	S SOB-CEASO	I ILINO DI	112	
	AA2									
	1	<u> </u>			PATENT DOCUM					
EXAMINER INITIAL		1	UMENT	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLAT	ION	
INITIAL	AB2	NUM	IDEK		·				Yes	
	122								No	
					uthor, Title, Date, Pe					
m	AC	<u>2</u>	Ferrara	& Henzel,	Biochem. Biophys. F	Res. Comm, 16	<u>1</u> :851-858 (1989)	- Abstract only	y.	
	AD	<u>2</u>	Ferrara	N. and Dav	is-Smyth, Endocrine	Rev., <u>18</u> :4-25	(1997)			
	AE	2	Folkhan	n, <u>J. Natl., (</u>	Cancer Inst., 82:4-6 (	(1991)				
	AF	2	Folkmar	netal IB	iol. Chem., 267:109	31-10934 (199	)2)			
				ot u, <u>s</u>	<u>101. C.10111., 207</u> .107	31 1033 (133		Ti o	2	
	AG	2	Heidara	n et al., Mo	l. Cell. Biol., 11:134	1-142 (1991)		T SI	12C	
	AH	2	Hori et a	al., Cancer	Res., <u>51</u> :6180-9184	(1991)		NOV 0 7	CEN	
	AI	2	Houck,	et al., J. Bio	ol. Chem., 267:2603	1-26037 (1992)	)	7,003		
	AJ	2	Hubbard	i, <u>EMBO J.</u>	, <u>16</u> :5572-5581 (FG	FR1) (1997)		NOV 0 7 2003 TECH CENTER 1600/2900		
	AK	2	Hubbard	l, et al., Na	ture, <u>372</u> :746-754 (1	994)		<del></del>		
	AL	2			chemistry, 3:10450-5					
	AM	<u>=</u> <u>2</u>	ļ		, <u>85</u> :149-158 (1996)					
					<u> </u>	524 2544 (152	0)			
	AN	2			Iol. Cell. Biol., 12:2:	554-2544 (199 				
	AO	2			<u>362</u> :841-843 (1993)					
	AP	2	Kinsella	, et al., Exp	. Cell Res., 199:56-6	52 (1992)		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	AQ	2	Klagsbu	rn & Soker	, Current Biology, 3:	699-702 (1993	3)			
	AR	2	Knighton	Knighton et al., <u>Science</u> , <u>253</u> :407-413 (1991)						
1	AS	2	Kumar a	nd Fidler, <u>I</u>	n Vivo, <u>18</u> :27-34 (19	998) – Abstrac	t only.			
EXAMINER		$\overline{\mathcal{A}}$ .	1	`	DATE CO	NSIDERED	0			
	Tuf	7/2					8-1-03			
					not citation is in conf					





Page 3 of 5

	FORM	PTO 144	19	***************************************	ATTY. DOCKET N	NO.	APPLICATION	NO		
INFORMAT	ZION DIS	CLOSUR	E STATE	MENT	0125-0016D2		09/939,832	CH	30	
/	018	E JOES	<u></u>	<u></u>	APPLICANT(S) McTigue et al.  FILING DATE August 28, 2001  GROUP 1631  OC  GROUP 1631					
	OCT O	1 2001 (S)			FILING DATE August 28, 2001		GROUP 1631	600/29	2001	
	A CONTRACTOR OF THE PARTY OF TH	ON CONT	<del> </del>	II S D	ATENT DOCUMEN	ITS .				
EXAMINER INITIAL	A THAI	DOC NUM	UMENT BER	DATE	NAME	CLAS	S SUB-CLASS	FILING	DAT	E
	AA3			FOREIG	L D A MENTE DOCUM	TENTEO.		1		
EXAMINER INITIAL		DOC	UMENT	DATE	N PATENT DOCUM COUNTRY	CLASS	SUB-CLASS	TRANSI	LATIO	N
IMIAL	AB3	NOM	DER		-				Ye No	- 1
					uthor, Title, Date, Pe					$\equiv$
-is	AC	3	Lev et a	l., <u>Proc. Na</u>	ttl. Acad. Sci. USA, 8	<u>89</u> :678-682 (19	992)			
	AD	3	Matsui,	T., et al., <u>S</u>	cience, 243:800-804 (	(1989)		TEC		
	AE	3	McLesk	ey et al., C	ancer Res., <u>53</u> :2168-2	2177 (1993)			NOV	ij
	AF	3	McRee	et al., <u>J. Str</u>	ruct. Biol., 125 (2-3):	156-165 (1999	) - Abstract only.	皿	0 7	Ī
	AG	3	Moham	madi et al.,	Cell, <u>86</u> :577-87 (199	96)		160	2003	
	AH	3	Mohami	madi et al.,	Science, 276:955-960	0 (1997)		1600/2900		
	AI	3	Mullis,	et al. Biotec	chnology, <u>24</u> :17-27 (1	1992) – Abstra	ct Only.			
	AJ	3	Parast e	t al., Bioch	emistry, <u>37(47)</u> :16788	8-16801 (11/0	5/1998)			
	AK	<u>3</u>	Pepper,	M.S., <u>Vasc</u>	. Med., 1:259-266 (1	996) – Abstrac	et Only.			
	AL	3	Reedjik,	, et al., <u>EM</u>	BO J., <u>11</u> :1365-1372	(1992)			·	
	AM	3	Risau, V	V., <u>FASEB</u>	<u>J., 9</u> :926-933 (1995)					
	AN	<u>3</u>	Schucht	er, et al., C	ancer Res., 51:682-68	37 (1991)				
	AO	<u>3</u>	Seetharr	n, et al., <u>Or</u>	ncogene, 10:135-147	(1995)				
¥	AP	<u>3</u>	Severins	son et al., ]	Mol. Cell. Biol., 10:80	01-809 (1990)				
	AQ	3	Shalaby	et al., Natu	re, <u>376</u> :576-579 (199	95)				
	AR	3	Shibuya	, et al., Onc	ogene, <u>5</u> :519-524 (19	990)		-		
	AS	3	Szekane	cz, et al., <u>J.</u>	Investig. Med., 46:2	7-41 (1998)			<u> </u>	
EXAMINER	The	A	·		DATE CON	NSIDERED	1-1-03			
•			-		not citation is in confe				gh	

								Page 5 of 5	Ħ	
INEODA	M A TI	FORM			in ATTACK	ATTY. DOCKET NO 0125-0016D2	D.	APPLICATION 09/939,832	NO. CENI	001
INFORM	MATIC	ON DIS	IP &	SURE STATE	0	APPLICANT(S) McTigue et al.			VTER 1	0 3
	(	OCT	0 1 7	non E	DEMARK OF	FILING DATE August 28, 2001		GROUP 1631	ER 1600/2900	2001
		\ <del>\</del>		.6	U.S. F	PATENT DOCUMENT	'S			
EXAMINE INITIAL	R	TO B		OCUMENT UMBER	DATE	NAME	CLAS	S SUB-CLASS	FILING	DATE
		AA5							····	
					FOREIG	N PATENT DOCUME	NTS			
EXAMINE INITIAL	R			OCUMENT UMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSL	ATION
	·	AB5								Yes No
	-					uthor, Title, Date, Perti				
-17	[ .	AC	5			n Purification: Principle				
		AD	<u>5</u>			, "Structure of the Tyro ex with Inhibitors," Sc			last Growt	h
		,AE	<u>5</u>			"The First Structure of ling the Molecular Basi				
		AF	<u>5</u>	the Cata	alytic Doma	ture-Based Design of a ain of the erbB Receptor ; 40: 1130-1135.				' J.
		AG	<u>5</u>						CEN CEN	70V
		AH	<u>5</u>						CENTER	7
		AI	<u>5</u>					•	1600	2003
		AS	<u>5</u>			1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -			1600/2900	
EXAMINE	R	p	6	n		DATE CONS	SIDERED	8-1-03		
EXAMINER citation if no	R: Inition	ial if ref	erence ince ar	considered, and not consider	whether or ered. Inclu	not citation is in confor de copy of this form wit	mance with I	MPEP 609. Draw nunication to Appl	line throug	gh